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Abstract The multifunctional enzyme tissue transgluta-
minase (TG2) is reported to both mediate and inhibit
tumour progression. To elucidate these different roles of
TG2, we established a series of stable-transfected mouse
colon carcinoma CT26 cells expressing a catalytically
active (wild type) and a transamidating-inactive TG2
(Cys277Ser) mutant. Comparison of the TG2-transfected
cells with the empty vector control indicated no differences
in cell proliferation, apoptosis and susceptibility to doxo-
rubicin, which correlated with no detectable changes in the
activation of the transcription factor NF-jB. TG2-trans-
fected cells showed increased expression of integrin b3,
and were more adherent and less migratory on fibronectin
than control cells. Direct interaction of TG2 with b3 inte-
grins was demonstrated by immunoprecipitation, suggest-
ing that TG2 acts as a coreceptor for fibronectin with b3
integrins. All cells expressed the same level of TGFb
receptors I and II, but only cells transfected with active
TG2 had increased levels of TGFb1 and matrix-deposited
fibronectin, which could be inhibited by TG2 site-directed
inhibitors. Moreover, only cells transfected with active
TG2 were capable of inhibiting tumour growth when
compared to the empty vector controls. We conclude that
in this colon carcinoma model increased levels of active
TG2 are unfavourable to tumour growth due to their role in
activation of TGFb1 and increased matrix deposition,
which in turn favours increased cell adhesion and a low-
ered migratory and invasive behaviour.
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Introduction
The communication between tumour cells and their
microenvironment, particularly their recognition of the
different extracellular matrix (ECM) ligands, is a key
process during tumour progression including tumour cell
proliferation, migration and matrix remodelling by these
cells (Ai et al. 2008). The multifunctional enzyme tissue
transglutaminase (TG2), which has important roles in cell
adhesion and migration, cell survival/death, matrix depo-
sition and angiogenesis, has been the focus of numerous
studies in cancer biology (Kotsakis and Griffin 2007;
Lentini et al. 2004). TG2 is the most ubiquitous member of
the transglutaminase family which crosslink proteins
through a Ca2?-dependent manner via e(c-glutamyl) lysine
bridges or via the incorporation of polyamines into peptide
bound c-glutamine residues (Griffin et al. 2002). TG2 is
found in the intracellular compartment (e.g., cytosol,
mitochondria, and nucleus), at the cell surface and in the
ECM. Under physiological conditions, its transamidating
activity normally remains latent within the cell due to low
Ca2? and the inhibitory effects of GTP/GDP (Smethurst
and Griffin 1996). Present thinking suggests that only when
Ca2? homeostasis is lost and when the cell is already
committed to cell death, does the crosslinking of intracellular
proteins normally occur leading to apoptosis (Gundemir
and Johnson 2009) and/or necrosis (Nicholas et al. 2003).
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Recent evidence has suggested in breast cancer cells, TG2
may act as a non-transamidating scaffold protein in the
intracellular environment by regulating cell migration,
through influencing the organisation of the actin cytoskel-
eton (Antonyak et al. 2009).
In the Ca2?-rich extracellular environment, TG2 may
also function in either a transamidating or a non-transam-
idating role. As a novel scaffold protein, TG2 may promote
cell adhesion through its ability either to act as an integrin
coreceptor for fibronectin (FN) or, once deposited into the
ECM and bound to FN, to function as a novel hetero-
complex via binding to syndecan-4. Neither of these
functions requires its transamidating activity (Akimov et al.
2000; Telci et al. 2008). In the extracellular environment,
TG2 can also function through its Ca2?-activated tran-
samidating activity to increase the rate of deposition of
ECM proteins such as FN and collagen I (Shweke et al.
2008; Verderio et al. 1999; Yuan et al. 2007), leading to
accumulation and changes in the ECM influencing both
cell adhesion and differentiation (Chau et al. 2005; Johnson
et al. 2007).
Given these multifunctional roles of TG2, it is not sur-
prising that reports have been contradictory as to whether
TG2 is inhibitory to, or required for tumour progression
(Grigoriev et al. 2001; Hand et al. 1988; Kotsakis and
Griffin 2007; Verderio et al. 1999). In recent studies, we
demonstrated that the crosslinking activity of TG2 leading
to ECM deposition and the inhibition of angiogenesis was
sufficient for tumour growth blockade following intratu-
mour injection of active TG2 into mice bearing CT26 colon
carcinoma tumours (Jones et al. 2006). In other studies,
increased expression of TG2 in a rat fibrosarcoma model
led to reduced tumour incidence (Johnson et al. 1994),
while increased tumour progression of the B16-F1 and
B16-F6 melanoma was observed in TG2 knockout animals
when compared to their respective wild type controls (Di
Giacomo et al. 2009; Jones et al. 2006). Contrary to these
findings, other workers have suggested that TG2 may act as
a cell survival protein in the activation of NF-jB by a
mechanism involving the intracellular crosslinking of the
IjB inhibitory subunit of the NF-jB complex (Mann et al.
2006; Verma and Mehta 2007b). In a recent study, it was
also demonstrated that a TG inhibitor KCC009, as well as
TG2 siRNA treatment, can disrupt the matrix FN assembly
by glioblastoma cells, suggesting that TG2 may be a
potential target in cancer chemotherapy (Yuan et al. 2007).
In order to distinguish the importance of the different
functional roles of TG2 we have established a series
of stable-transfected mouse colon carcinoma CT26
expressing catalytically active (wild type) and inactive
TG2 (Cys277Ser mutant). Then in both in vitro and in vivo
studies, we further investigated the behaviours of these cell
clones with their respective controls to elucidate the
different contributions that TG2 might have on the growth
and progression of this mouse colon carcinoma.
Materials and methods
Cell culture
CT26 mouse colon carcinoma cells (ATCC no. 2638) were
kindly provided by Prof. R. Rees (Nottingham Trent Uni-
versity, UK) and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% (v/v) heat-inactivated
foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml
penicillin and 100 lg/ml streptomycin. Transfected CT26
cells were maintained in the same medium supplemented
with 400 lg/ml G418.
Isolation of CT26 (transfected with active and inactive
TG2 constructs or the empty vector) from balb/c hosts was
carried out by incubating 5 mm square pieces in DMEM,
100 U/ml penicillin and 100 lg/ml streptomycin, 0.2% (w/v)
dispase (Gibco) at 4C overnight. Following incubation, the
tumour samples were further cut into 1–2 mm pieces using a
scalpel in a rocking motion and placed into six-well plates
with 0.2 ml of fully supplemented DMEM containing 10%
(v/v) FBS. A further 1.5 ml of growth medium was added to
the wells after 7–10 days. Following three rounds of pas-
saging, isolated tumour cells were cultured in a standard cell
growth media supplemented with 400 lg/ml G418.
Transfections
Transfection of CT26 mouse colon carcinoma cells with
pSV-Neo and pSG5 expression vectors containing wild
type and mutant (Cys277Ser) TG2 cDNA was achieved by
co-transfecting cells with the TG2-containing vector (5 lg)
and the selection pSV-Neo plasmid (0.5 lg) using a nu-
cleofector system (AMAXA Biosystems) according to the
manufacturer’s protocol. Transfected clones resistant to
400 lg/ml G418 (Geneticin, Calbiochem) were screened
for overexpression of TG2 by western blotting a high
expressing TG2 clones selected.
Transglutaminase activity assays
Transglutaminase activity in cell lysates, obtained after
sonication of cells, was measured by the incorporation of
14C-labelled putrescine into N,N0-dimethylcasein as descri-
bed previously (Lorand et al. 1972; Jones et al. 1997). In
situ cell surface-associated TG activity was measured by
incorporation of biotinylated cadaverine into deoxycholate-
insoluble fibronectin as previously described (Jones et al.
1997). 2 9 104 cells/well in serum-free DMEM containing
0.132 mM biotin-X-cadaverine (Molecular Probes, Oregon,
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USA) were added to the FN-precoated 96-well plates and
incubated for 2 h at 37C. The reaction was stopped by
2 mM EDTA in PBS, pH 7.4, and the cells were removed
by incubation with 0.1% (w/v) deoxycholate in PBS con-
taining 2 mM EDTA, pH 7.4 for 10 min at room tempera-
ture. Biotin–cadaverine incorporation into FN was detected
using an extravidin peroxidase conjugate diluted 1:1,000 in
blocking buffer.
Detection of antigens in the whole cell lysates, cellular
fraction, growth medium, matrix or tumour
homogenates
Tumour specimens or cells were sonicated in 250 mM
sucrose, 2 mM EDTA in 5 mM Tris–HCl, pH 7.4, with
protease inhibitor cocktail (Sigma, UK). Homogenates
solubilised in Laemmli sample buffer were separated by
SDS-PAGE (8% gels), followed by Western blotting.
Monoclonal antibody Cub7402 recognizing human TG2,
which does not cross react with mouse, was used for the
detection of TG2. In cell lysates, monoclonal antibody
TG100 which has a broader specificity was also used.
TG2 secreted into the media of transfected CT26 was
detected as described previously (Balklava et al. 2002).
Briefly, serum-free medium was incubated with confluent
cultures for 8 h. Culture supernatants were precipitated
with 10% (w/v) ice cold trichloroacetic acid (TCA). Protein
pellets were washed sequentially with ice cold 10% (w/v)
TCA, 0.5 ml ethanol–acetone (ratio 1:1) and acetone, and
air dried prior to resuspension in 29 Laemmli sample
buffer. TG2 was detected by Western blotting as described
above.
Deoxycholate-insoluble ECM samples were collected
after seeding the cells into 60 mm dishes for 16 h. Fol-
lowing detaching of the cells in 2 mM EDTA in PBS, pH
7.4, the remaining matrix was washed once with 2%
sodium deoxycholate in Tris–HCl, pH 8.8, containing
10 mM EDTA and 0.5 mM PMSF (Akimov and Belkin
2001) and collected in 29 Laemmli buffer. Following
separation by SDS gel electrophoresis using 6% gels, the
presence of FN antigen was transferred to a nitrocellulose
membrane and then detected by immunoblotting using
rabbit anti-FN polyclonal antibody (Sigma–Aldrich).
Cell proliferation, apoptosis and doxorubicin
susceptibility assays
Viable cell number was measured by XTT according to the
manufacturer’s protocol (Roche Diagnostics, UK). Briefly,
CT26 cells (3,000/well) were seeded in 96-well plates and
the XTT assay was performed after 12, 24, 36, 48 and 72 h-
incubation. Programmed cell death in TG2-transfected
CT26 clones was assessed using a commercial Caspase-3
Assay system (Promega, Southampton, UK), according to
the manufacturer’s protocol. CT26 cells (2 9 106 cells/T25
flask) were incubated for 24 h. The apoptotic index of the
cell line was measured by the ability of caspase-3 to cleave
Ac-DEVD-p-nitroaniline substrate and release a chromo-
phore, p-nitroaniline (pNA). Apoptosis in the positive
controls was induced using 1 lM of the protein kinase
inhibitor staurosporine, whereas irreversible and cell-per-
meable pan-caspase inhibitor Z-VAD-FMK was added to a
final concentration of 50 lM in the negative control cul-
tures together with 1 lM staurosporine. To investigate the
susceptibility of CT26 cell clones to doxorubicin, different
concentrations of doxorubicin (0.5, 1, 10 lg/ml) were used
to treat the CT26 cell clones (1,000 cells/well) for 48, 96,
120 and 144 h time courses and XTT assay was performed
as before.
Cell attachment assay
CT26 cell clones (2 9 105/well) in serum-free DMEM
were added to a 96-well FN-coated plates (5 lg/ml, incu-
bated at 4C overnight) and incubated for 40 min at 37C,
5% (v/v) CO2. The images of the crystal violet stained cells
were stained captured using an Olympus digital camera.
Dessicated cells were finally solubilised by addition of
100 ll/well 30% (v/v) acetic acid, and absorbance was read
at 540 nm on a Spectrafluor plate reader.
Fluorescent measurement of cellular migration
Fluoroblock nitrocellulose membranes (6 lm pore size,
BD Biosciences, UK) were coated with FN as described
above. 106 cells/ml in serum-free DMEM placed into the
top chamber of the wells were allowed to migrate through
the FN-coated Fluoroblock nitrocellulose member for 72 h,
while the culture medium with 10% (v/v) FBS as a che-
moattractant was then added to the bottom wells. Inserts
were transferred to 24-well glass-bottom plates containing
4 lg/ml calcein AM (Molecular Probes, Eugene, USA) in
Hanks balanced salt solution and incubated at 37C for
90 min. The signals were detected (485/530 nm excitation/
emission) from bottom-to-top using a SpectraFluor plate
reader.
Immunofluorescent staining for extracellular TG2
Extracellular TG2 was measured by in situ immunofluo-
rescent staining as described previously (Verderio et al.
1998). Live CT26 cell clones were allowed to grow for
72 h to facilitate ECM deposition and then incubated with
the anti-TG2 monoclonal Cub7402. After fixation, an
FITC-conjugated anti-mouse IgG secondary antibody was
used to reveal ECM-associated TG2 and the fluorescence
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signal was visualised by laser confocal microscopy using a
Leica TCSNT system (Leica, Heidelberg, Germany).
Flow cytometry
Transfected CT26 cells seeded in 6-cm petri dishes were
detached with 2 mM EDTA in PBS, pH 7.4. The suspen-
sion containing 2 9 106 live cells/ml was incubated with
3 lg/ml of either Cub7402 or non-immune mouse IgGj
(Sigma) in serum-free medium for 1.5 h at 4C. Following
washing, the cells were incubated with the FITC-conjugate
secondary antibody (3 lg/ml) for 1 h at 4C and the
washed cells were then fixed in 0.5% (w/v) formaldehyde,
prior to analysis for the presence of cell surface TG2 in a
DAKO Galaxy flow cytometer (DAKO, UK). Resulting
values represent mean fluorescence intensity. Scattering
images were analysed using WinMDI software (Scripps
Research Institute). Values represent percentage of peak
shift compared to the isotype control gate.
Co-immunoprecipitation
CT26 clone lysates were collected in lysis buffer with
500 lM TG inhibitor R283 (Griffin et al. 2008) as
described previously (Telci et al. 2008). Cell lysates
(150 lg) were pre-cleared by incubating with non-specific
rabbit IgG (Santa Cruz, USA) and the protein A-Sepharose
bead slurry (GE Healthcaree, Sweden) at 4C for 1 h and
90 min, respectively. They were then incubated with
0.5 lg of rabbit anti-b3 integrin antibody (Cell signalling,
UK) for 90 min at 4C, followed by 50 ll of protein
A-Sepharose bead slurry for 2 h at 4C. The b3 immuno-
complex was collected in 29 Laemmli sample buffer and
assayed via Western blotting to detect TG2.
Detection of the TGFb1 secretion via ELISA
CT26 cell clones were seeded into 24-well plate and
allowed to adhere for 2 h in complete medium. Growth
factor-free replacement medium was replaced and supple-
mented with 10 lg/ml of purified guinea pig liver TG
(gplTG) or 500 lM of the site-directed transglutaminase
inhibitors R283 or R294 (Griffin et al. 2008). The cells
were treated for 16 h and the culture medium was collected
for TGFb1 detection via ELISA according to the manu-
facturer’s introduction (eBiosciences).
Detection of the presence of NF-jB in cytosol
and nuclei fractions
The cytosol and nuclei fractions from Neo1 and TG3 CT26
cells were prepared using the activation assay kit from
FIVEphoton according to the manufacturer’s instructions.
The presence of NF-jB-p65 within the cytosol and nuclear
fractions was detected via Western blotting using an anti-
NF-jB (p-65) antibody (Cell Signalling, UK), while the
phosphorylated form of IjB in the cytosol fraction was
detected using an anti-phosphorylated-IjB antibody (Cell
Signalling, UK).
Animal studies
Animal procedures were carried out in accordance with the
UK Home Office Animal Act (1986). Female balb/c mice
(Harlan Olac, UK) were inoculated with 2 9 103 trans-
fected CT26 cells in 0.1 ml DMEM by subcutaneous
injection in the right flank. Subcutaneous tumour growth
was measured at 2 days intervals with a calliper and ani-
mals were killed before the individual tumour diameter
exceeded 1 cm2.
Statistical analysis
Differences between datasets were determined by the
Mann–Whitney or student t test using Minitab or Sigma
Stats packages at a significance level of p \ 0.05.
Results
Screening CT26 clones for total TG2 antigen
and activity
Following selection by G418-resistance, the active TG2
clones TG3 and TG5, and inactive mutant (Cys277Ser)
transfected clones INA13 and 14, together with control
clones Neo1 and Neo2, were chosen for further study
(Fig. 1a). Measurement of TG activity in cell lysates
indicated that the inactive mutant TG2 construct did not
confer any further activity to the CT26 cells, compared to
the transfected controls. Both the transfected control cells
and the inactive mutant transfected cells had no detectable
activity (Fig. 1b), which was confirmed by Western blot-
ting for the Neo1 and Neo2 control cells. All clones were
characterised by a phenotype of rod-like cell bodies
extended in length, with no major morphological differ-
ences observed (Fig. 1c). Cell-surface TG activity was only
detectable in clones TG3 and TG5 (Fig. 1d).
Cell surface and matrix distribution of TG2 antigen
Flow cytometric analysis confirmed the presence of TG2 at
the cell surface of both active and inactive mutant TG2-
transfected clones (Fig. 2a). In situ fluorescence-stained
matrix-associated TG2 revealed patchy fibrillar staining of
the externalised enzyme in clones TG3, and TG5, whereas
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the ECM of the inactive CT26 clones was found to be
devoid of enzyme (Fig. 2b), which is in keeping with
earlier studies in fibroblasts (Balklava et al. 2002). Western
blotting of serum-free cell culture media from confluent
cultures revealed the presence of the enzyme in the med-
ium of the active TG2 clones only (Fig. 2c).
Overexpression of TG2 does not affect cell
proliferation, apoptosis or the susceptibility
to doxorubicin
Over a time course of 72 h (Fig. 3a), no difference in viable
cell number was observed between the cells transfected
with the active or inactive TG2 or the empty vector-trans-
fection ruling out any influence of TG2 on cell proliferation.
Similarly, apoptotic indices of the different clones when
measured by caspase-3 activity were also very low and
comparable throughout all clones (Fig. 3b). Previous work
suggested that a high level of TG2 was discovered in drug-
resistant breast cancer cell MCF-7 (Herman et al. 2006).
We, therefore, investigated the effect of doxorubicin on the
CT26 cell clones. No significant difference in cell viability
was found between the three clones Neo1, INA14 and TG3
at the concentrations 0.5, 1, and 10 lg/ml, suggesting the
over-expression of either active or inactive mutant TG2
does not affect the susceptibility of the CT26 colon carci-
noma to the anti-cancer drug doxorubicin (Fig. 3c).
Cell adhesion and migratory behaviour of CT26 clones:
relationship to expression of integrins b1, b3, b5
and syndecan-4
CT26 clones overexpressing the active and inactive mutant
forms of TG2 demonstrated a significant increase in cell
adhesion on fibronectin-coated surfaces when compared to
the transfected controls (Fig. 4a(i) and (ii)). This is consis-
tent with their migratory behaviour on FN-coated surfaces,
which showed reduced migration in both the active and
mutant TG2-transfected clones, compared to the transfected
controls (Fig. 4b).
Fig. 1 The establishment of the CT26 cell clones following trans-
fection with active and inactive TG2. a Western blotting was
performed to detect the presence of TG2 antigen within the CT26 cell
clones, Neo 1 and 2 (CT26 cell transfected with empty vector),
INA13 and 14 (CT26 cells transfected with inactive TG2) and TG3
and 5 (CT26 cells transfected with active TG2) using mouse anti-TG2
monoclonal antibody Cub7402 (Neomarkers). Guinea pig liver TG
(gplTG) was used as the TG2 standard, while a-tubulin was used as
the equal-loading standard. b Total TG activity of CT26 clones was
measured by the (14C)-putrescine incorporation assay using the
lysates from 4 9 106 cells as described in the ‘‘Materials and
methods’’. Results represent mean values ± SD. Asterisk represents
significant difference (p \ 0.05) between the experimental groups
and the control groups (the empty vector-transfected CT26 cells).
c CT26 clone morphology was examined after staining with 0.5% (w/
v) crystal violet. Images were captured using an Olympus digital
camera attached to a light microscope (Bar 50 lm), which represen-
tative of nine images from each group. d Cell surface-associated TG
activity was measured by incorporation of biotinylated cadaverine
into deoxycholate-insoluble fibronectin as described in the ‘‘Materials
and methods’’. Results represent mean values ± SD. Asterisk repre-
sents significant difference (p \ 0.05) between the experimental
groups and the control groups (Neo1 and Neo2)
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Analysis of the different cell surface receptors showed
that TG2 might associate with indicated increased expres-
sion levels of b3 integrin in both active (TG3 and TG5) and
inactive mutant INA13 and 14 clones (Fig. 4c). Changes in
the expression of b1 and b5 integrins and syndecan-4,
which might also account for the observed changes in cell
adhesion, were not detectable. Immunoprecipitation of
TG2 in the Neo1, INA14, and the TG3 and TG5 cell clones
using an anti-b3 integrin antibody confirmed the direct
association of the two proteins following western blotting
and immunoprobing with anti-TG2 antibody (Fig. 4d).
Measurement of matrix FN and TGFb1 in the CT26
transfected clones
Measurement of TGFb1 levels in the cell culture medium
from the clones Neo1, INA14 and TG3 (Fig. 5a) indicated a
significant increase in the TGFb1 levels in TG3, compared
to the transfected control cells (Neo1) and the inactive
mutant clone (INA14). The site-directed TG inhibitors
R283 and R294 significantly (p \ 0.05.) reduced the active
levels of TGFb1 produced by clone TG3, indicating its
dependence on TG activity. Interestingly, the inhibitor
R283, which unlike R294 is membrane permeable, also
reduced the levels of TGFb1 in the INA14 clone, when
compared to control cells which may be due to other effects
rather than its inhibition of TG2 given the ability of this
inhibitor to penetrate the cell membrane. No significant
reduction in TGFb1 levels was found with the non-perme-
able TG2 inhibitor R294 in this particular clone. Exoge-
nously purified gplTG added to the cell culture medium
gave rise to a comparable increase in TGFb1 in all the
clones treated confirming the importance of TG2 in TGFb1
activation. Equal expression levels of TGFb receptors I and
II were found in all of the three clones—Neo1, INA14 and
TG3––when analysed by Western blotting (Fig. 5b). One
important effect of TGFb1 is related to increased deposition
of ECM proteins such as collagen and FN (Rosenkranz
Fig. 2 The distribution of TG2 in CT26 cell clones. a Cell surface
TG2 antigen was detected by flow cytometry using a DAKO Galaxy
flow cytometer as described in the ‘‘Materials and methods’’. An anti-
mouse IgGj was used as the negative control antibody. Scattering
images were further analysed using the WinMDI application. Values
represent percentage of peak shift compared to the isotype control
gate. b Deposition of the extracellular TG2 antigen into the ECM of
the CT26 clones transfected with active (TG3 and 5) and inactive
(INA13 and 14) TG2 was detected by in situ immunostaining as
described in the ‘‘Materials and methods’’. Fixed cells were counter-
stained with propidium iodide (PI). Images of TG2 antigen were
captured under the FITC filter (top panels) of a Leica TCSNT
confocal microscope. Merged images of TG2 antigen with PI staining
observed using the TRITC filter (bottom panels). Bar 50 lm. The
image shown is representative of nine images from each group. c TG2
secreted in the culture media of TG2-transfected CT26 cells was
detected as described in the ‘‘Materials and methods’’
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2004). The levels of deoxycholate-insoluble FN matrix
measured by Western blotting in the different clones indi-
cated that both TG3 and TG5 contained a much higher level
of both monomeric and polymerised FN (unable to enter the
resolving gel), compared to the transfected Neo1 control
and the clone transfected with the inactive mutant TG2
(INA14), which both deposited very little matrix FN.
However, when cells were treated with equal amounts of
exogenous gplTG, the levels of matrix-associated FN
(particularly polymerised FN) increased in all the different
clones (Fig. 5c), thus paralleling the increases found for
TGFb1 when TG2 was added exogenously.
Levels of NF-jB activation in the transfected CT26
clones
We next assessed whether TG2 could increase the active
NF-jB levels in the CT26 clones transfected with the
active and inactive mutant TG2. As shown in Fig. 5d, no
significant difference of NF-jB activation, as measured by
the levels of p65 in the nuclear fraction, could be detected
in the different clones studied. Moreover, the levels of p65
and the free inhibitory binding protein IjB (in its phos-
phorylated form) in the cytosol fraction were also compa-
rable in the different clones. In addition, NF-jB activation,
as measured by the above parameters, was not affected by
the addition of the site-directed TG inhibitors R283 and
R281 (Griffin et al. 2008), when added to the different
clones (Fig. 5d), which rules out the involvement of TG2
in the activation of NF-jB in the TG2-transfected CT26
colon cancer cell lines.
The effect of overexpression of TG2 in CT26
on tumour growth and animal survival
Tumour incidence was found to be comparable in all six
clones but the growth of the CT26 clones TG5 and TG3
containing active TG2 was significantly decreased when
compared to the Neo1 and Neo2 controls at the time points
from 19 days onwards (Fig. 6a). The inactive transfected
Fig. 3 The effect of TG2 on the CT26 cell proliferation, apoptosis
and susceptibility to doxorubicin. a Viable cell numbers of the
different CT26 cell clones were counted by the XTT assay after 12,
24, 48 and 72 h growth by measuring the absorbance at 490 and
750 nm as described in the ‘‘Materials and methods’’. Results
represent mean values ± SD. b Programmed cell death was measured
by caspase-3 activity detected in CT26 clone lysates, 16 h post-
seeding, as described in the ‘‘Materials and methods’’, and was
expressed as pmol of pNA liberated per hour by reference to a pNA
standard curve. Addition of 1 lM staurosporine (staur) to cultures
was used as the positive control, whereas staurosporine and an
appropriate apoptosis inhibitor was used as the negative control
incubation with (staur. ? inh). Results represent mean values ± SD.
c To investigate the susceptibility of CT26 cell clones to doxorubicin,
CT26 cells (1,000 cells/well) were incubated with different concen-
trations of doxorubicin (0.5, 1, 10 lg/ml) for 48, 96, 120 and 144 h
and XTT assay was performed using a microplate reader at 490 and
750 nm. Results represent mean values ± SD
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controls INA13 and 14 did not show any significant dif-
ference in growth when compared to the Neo1 and Neo2
control groups. This decrease in tumour growth in the
active TG2-transfected clones was accompanied by an
increase in the percentage animal survival (Fig. 6b). The
TG5 clone, which when injected expressed less active TG2
than clone TG3, demonstrated both the slowest growth rate
and the best percentage of animals surviving. Both clones
INA13 and INA14 transfected with inactive Cys277Ser
mutant showed tumour growth rates and animal survival
percentages more comparable to the transfected control
clones. Inspection of the liver and lungs at tumour harvest
indicated no detectable signs of secondary tumours.
Immuno-probing of western blots obtained from tumour
tissue at 26 days growth for the presence of human TG2
indicated its presence in all the TG2-transfected clones
although somewhat reduced (Fig. 6c), compared to the
original cells used for inoculation. The amount of TG2
antigen present in TG3 tumours was reduced compared to
that found in TG5, which may account for the difference in
tumour growth rates of these two clones transfected with
the active TG2. To confirm this selective reduction in TG2
in clone TG3 during tumour growth, tumours at day 26
were resected and CT26 cells were selected from the
tumour mass in the presence of G418. Assay for TG2
antigen in the cultured cells by western blotting confirmed
that a reduction in TG2 antigen had occurred in clone TG3,
when compared to clone TG5, during tumour growth
(Fig. 6d), thus confirming what was found in the tumour
tissue.
Fig. 4 The effect of TG2 on cell adhesion and migration and
detection of cell surface receptors. a Attachment of CT26 clones on
fibronectin-coated surfaces was undertaken as described in the
‘‘Materials and methods’’. (i) Images are representative of three
non-overlapping fields, obtained from four separate samples (Bar
100 lm). (ii) stained cells were further solubilised in 30% (v/v) acetic
acid for 30 min at room temperature and resulting absorbance was
recorded at 540 nm using a SpectraFluor plate reader. Results are
expressed as mean value ± SD from two independent experiments.
Asterisk represents significant difference (p \ 0.05) between the
experimental groups and the control groups (the empty vector-
transfected CT26 cells). b The expression of TG2 on the migration of
CT26 clones was undertaken on FN-coated Fluoroblock nitrocellulose
membranes as described in the ‘‘Materials and methods’’. Results
represent mean values ± SD from three separate experiments.
Asterisk represents significant difference (p \ 0.05) between the
experimental groups and the control groups (the Neo1 and 2 clones).
c Western blotting was performed to detect the presence of the cell
surface receptors b1, 3 and 5 integrins and syndecan-4 in CT26 clones
using Western blotting as described in ‘‘Materials and methods’’. The
membranes were re-probed for a-tubulin detection as a standard for
the equal loading. d The interaction between b3 integrins and TG2
was investigated by co-immunoprecipitation using anti-b3 antibody to
pull down the b3 immuno-complex and Western blotting was used to
detect the presence of TG2 antigen within this complex using anti-
TG2 antibody Cub7402
916 P. Kotsakis et al.
123
Discussion
In this study, we have undertaken both in vitro and in
vivo studies on a mouse CT26 colon carcinoma cell line
with the objective of elucidating the different contribu-
tions of the multifunctional enzyme TG2 on the growth
and progression of this mouse colon carcinoma model.
Studies on cells transfected with both the active wild type
enzyme and the inactive Cys277Ser mutant indicated very
little difference in cell morphology, cell proliferation and
endogenous rates of apoptosis, when compared to the
empty vector-transfected controls. However, when cells
transfected with the active wild type TG2 were subcuta-
neously injected into mice, the tumour growth rates were
significantly slower and percentage animal survival was
increased, in comparison to animals injected with the
other transfected CT26 cells. Examination of tumour tis-
sue for the presence of TG2 indicated that it was still
detectable in all the tumours, where the original cells
contained the transfected enzyme although slightly lower
in the tumours derived from the active clone TG3.
Moreover, when cells were cultured from resected tumour
tissue and the CT26 cells selected for in G418, assay of
TG2 antigen in these cells confirmed a reduced amount of
TG2 antigen in TG3 cells compared to TG5 cells. This
reduction in TG2 in TG3 clones may explain why this
clone grew faster than the other active TG2-transfected
clone TG5, which originally had less TG2. These data are
consistent with much earlier studies investigating the
effects of TG2 expression on tumour growth where the
active TG2 was transfected into a highly metastatic
fibrosarcoma cell line (Johnson et al. 1994) and into a
neuroblastoma cell line (Piacentini et al. 1996). However,
in both the latter studies, cells carrying inactive TG2
Cys277Ser mutant were not studied and no detailed
mechanisms for the observations were given. They are
also consistent with the observation of increased tumour
growth and progression of the B16 melanoma (F1and F6)
in a mouse TG2 knockout model (Di Giacomo et al.
2009; Jones et al. 2006). Taking on board the proposed
physiological functions for TG2 (Collighan and Griffin
2009; Griffin et al. 2002) and those proposed for its roles
in cancer progression (Kotsakis and Griffin 2007; Mehta
2009; Verma and Mehta 2007a), our next step was to
Fig. 5 The effect of TG2 on TGFb1 release and its related matrix FN
deposition and NF-jB activation. a The release of TGFb1 into the
medium of CT26 cell clones. CT26 cell clones were detected by
ELISA as described in the ‘‘Materials and methods’’. Results
represent mean values ± SD. Asterisk represents significant differ-
ence (p \ 0.05) between the experimental groups and the control
groups (the non-treated Neo1 cells). b Detection of the presence of
TGFbRI and TGFbRII in CT26 cell clones was undertaken by
Western blotting using specific antibodies as described in the
‘‘Materials and methods’’. The membranes were re-probed for
a-tubulin detection as a standard for equal loading. c For detecting
matrix-FN deposition, the deoxycholate-insoluble matrix samples
were collected and the FN present detected by Western blotting as
described in the ‘‘Materials and methods’’. d For measurement of the
activation of NF-jB in CT26 cell clones the cytosol and nuclei
fractions from Neo1 and TG3 CT26 cell clones were prepared using
the activation assay kit as described in ‘‘Materials and methods’’.
Western blotting was performed to detect the antigens of NF-jB and
phosphorylated IjB within the samples using specific antibodies. The
membrane with the cytosol fraction samples was then re-probed to
detect a-tubulin as a measure of equal loading
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elucidate the mechanism(s) for this effect of the active
TG2 on tumour growth.
One of the important functions of TG2 pertains to its
role in the extracellular environment where it may influ-
ence both cell adhesion (Akimov et al. 2000; Telci et al.
2008; Verderio et al. 2003) and matrix accumulation/sta-
bility (Akimov and Belkin 2001; Chau et al. 2005). In all
TG2-transfected clones, TG2 was found at the cell surface,
but in keeping with our earlier studies (Balklava et al.
2002; Gaudry et al. 1999), only in the clones transfected
with the active wild type enzyme was it found deposited in
the extracellular matrix (ECM). The presence of the
enzyme at the cell surface either in its active or inactive
mutant form led to an increase in cell adhesion on fibro-
nectin (FN) by a mechanism probably linked to its ability
to act as an integrin coreceptor for FN (Akimov et al.
2000), since overexpression of TG2 in the CT26 cells is
accompanied by an increase in the b3 integrin, not present
in the controls. Moreover, immunoprecipitation studies
revealed the direct association of TG2 with b3 integrin. No
change was found in other TG2-related cell adhesion cell
surface receptors, i.e. b1 and b5 integrins and syndecan-4.
b3 integrins can mediate cell adhesion and migration on
FN via their binding to the RGD cell binding-domain.
Interestingly, like TG2, it plays important roles in both
wound healing and angiogenesis (Switala-Jelen et al. 2004;
Tadokoro et al. 2003) and has been linked to TG2 function
in macrophage phagocytosis (Toth et al. 2009). The
increased cell adhesion on FN exhibited by the TG2-
transfected cells probably explains their reduced migration
on FN surfaces. However, given that both clones trans-
fected with either active wild type or the inactive mutant
display a similar adhesive/migratory phenotype, it does not
account for the differences in tumour growth observed
Fig. 6 The effect of TG2 on CT26 tumour growth. Exponentially
growing CT26 clones were harvested and resuspended to a final
concentration of 2 9 104 cells/ml in DMEM, prior to subcutaneous
implantation of 100 ll cell suspensions into 8-week-old balb/c mice.
Following injections, animals were checked every 2 days for tumour
development. The results shown are from a representative experiment
undertaken in duplicate and indicate mean values (n = 6). a Average
tumour growth rate expressed in mm2 was measured up to 38 days
post-injection. b Percentage animal survival, following injection of
the malignant CT26 clones. c For detection of TG2 expression in
tumour samples, tumour specimens were homogenised in 250 mM
sucrose, 2 mM EDTA, 5 mM Tris–HCl in the presence of protease
inhibitors to yield a 20% (w/v) final homogenate concentration. 20 lg
of total protein was analysed for TG2 antigen by Western blotting,
gplTG was used as a positive control. d CT26 tumour cells from Balb/
c animals were isolated as introduced in ‘‘Materials and methods’’ and
Western blotting was performed to detect the presence of TG2
antigen. Western blots were undertaken three times and used tubulin
as a marker for equal protein loading, while gplTG was used as a
positive control
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between these clones. Since TG2 may influence cell sur-
vival of tumours via activation of NF-jB (Mann et al.
2006; Verma and Mehta 2007b), we investigated whether
the level of NF-jB was different in each of the transfected
clones to rule out its influence on tumour growth. All
representative clones tested showed no differences in the
activation of NF-jB, which probably explains their com-
parable levels of endogenous apoptosis and also their
comparable susceptibility to doxorubicin.
The importance of TG2 in ECM deposition and sta-
bilization is now well established (Chau et al. 2005;
Collighan and Griffin 2009; Fisher et al. 2009). TG2
activity can influence this process either directly by
crosslinking (Chau et al. 2005) or indirectly by the
crosslinking and activation of matrix-associated latent
TGFb (Verderio et al. 1999). Accumulating reports indi-
cate that TG2-mediated matrix changes can inhibit tumour
invasion (Di Giacomo et al. 2009; Jones et al. 2006;
Mangala et al. 2005), while a TG2-crosslinked extracel-
lular matrix can also inhibit angiogenesis (Jones et al.
2006; Myrsky et al. 2009). We recently demonstrated that
intratumour injection of TG2 into mice bearing the CT26
tumours led to induction of fibrosis and tumour regression
(Jones et al. 2006). Turning our attention to assess whether
the levels of the fibrotic cytokine TGFb1 were different
between the CT26 clones, we found increased levels of
TGFb1 in the medium of the active TG2 transfected clone,
which could be inhibited by the inclusion of site-directed
TG inhibitors in the culture medium. Moreover, addition
of exogenous TG2 to the cell cultures of the inactive
mutant or the empty vector cells raised the level of active
TGFb1 to the level of the clone carrying the active
enzyme, thus supporting earlier findings for the involve-
ment of TG2 in TGFb1 activation (Huang et al. 2009;
Telci et al. 2009).
Importantly, we found that all the CT26 clones inves-
tigated carried the TGFb receptor I (TGFbRI) and TGFb
receptor II (TGFbRII). Hence any increase in the levels of
active TGFb1 such as those found in the active TG2
transfected clone should lead to autocrine stimulation of
the CT26 clone resulting in increased matrix protein
deposition. Analysis of the transfected clones clearly
indicated an increase of deoxycholate-insoluble matrix FN
found in the two clones transfected with the active TG2.
Moreover, the increased levels of TGFb1 produced by the
active TG2 transfected clone could also lead to paracrine
stimulation of stromal cells in the tumour environment.
Evidence, that this increase in FN deposition, was linked to
increased levels of extracellular TG2 was demonstrated by
the increased levels of FN found in the clones carrying the
inactive mutant TG2 and the empty vector, when TG2 was
added to the medium of these cells. Our data therefore
indicate that the CT26 cells transfected with the active TG2
secrete this enzyme into the ECM, where it is able to
activate latent matrix bound TGFb1. The consequence is
the increased deposition and stabilization of matrix pro-
teins such as FN either by the tumour cells themselves or
by surrounding stromal cells, leading to increased cell
adhesion, decreased migratory ability and inhibited inva-
sion of the surrounding matrix, thus slowing down tumour
growth and progression.
Over the last two decades, various reports have looked
at the relationship between cancer development and TG2
expression (Jones et al. 2006; Kotsakis and Griffin 2007;
Mehta 2009). The take home message has been that TG2
expression and activity is generally altered when the
tumour cells are compared to normal cells (Ientile et al.
2007; Kotsakis and Griffin 2007). Whether this is an
increase or a reduction in TG2 activity either through
reduced expression or the expression of altered forms
(Di Giacomo et al. 2009) seems to be dependent on tumour
type and stage of tumour progression. In the early stages of
tumour growth and progression decreased TG2 at the cell
surface and in the matrix would facilitate increased inva-
sion and migratory ability. In some cancer cells, cell sur-
face TG2 may be reduced through degradation by MMPs
(Belkin et al. 2004), or can be down-regulated by activated
H-Ras (Akimov and Belkin 2003). However, in the later
stages of tumour progression, following increased selection
for the metastatic phenotype, TG2 expression may be
important in cell mechanisms facilitating cell survival. In
this report, we validate earlier findings (Barnes et al. 1985;
Hand et al. 1988; Jones et al. 2006; Knight et al. 1990) that
reduced TG2 expression is required during tumour growth
and progression, and provides a mechanism relating to the
importance of the enzyme in matrix synthesis and deposi-
tion explaining why this reduction should occur.
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